

Correction: *British Society of Gastroenterology consensus guidelines on the management of inflammatory bowel disease in adults*

Lamb CA, Kennedy NA, Raine T, *et al.* British Society of Gastroenterology consensus guidelines on the management of inflammatory bowel disease in adults. *Gut* 2019;68:S1–s106. doi:10.1136/gutjnl-2019-318484.

Table 3

Table contains the original scoring where normal = 1 (ie range 3-11) and should be normal = 0 (range 0-8). Also reference 35 in the table heading should be reference 36.

Table 8

Legend for table 8 should be: “Endoscopic activity: Remission, score 0-2; Mild, score 3-6; Moderate, score 7-15; Severe, score ≥ 16 ”

3.9.7 UNIFI

Results for the 8-weekly and 12-weekly groups for the UNIFI maintenance study are the wrong way round. The sentence "In the maintenance continuation study, 523 patients with clinical response at week eight were re-randomised to placebo, 8-weekly or 12-weekly dosing, with week 44 remission rates of 24%, 38.4% and 43.8%, respectively" should be "In the maintenance continuation study, 523 patients with clinical response at week eight were re-randomised to placebo, 8-weekly or 12-weekly dosing, with week 44 remission rates of 24%, 43.8% and 38.4%, respectively”

5.13.2 IBD-related cancer chemoprevention with mesalazine

The sentence states a dose-dependent protective effect was noted with 5-ASA with a minimum dose of 1.2g¹¹⁶⁹ or 2g.¹¹⁷¹ In fact both references support a minimum dose of 1.2g. “or 2g” should be removed from sentence.

© Author(s) (or their employer(s)) 2021. No commercial re-use. See rights and permissions. Published by BMJ.

Gut 2021;70:e2. doi:10.1136/gutjnl-2019-318484corr1

